Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945875 | 0.85 | LMNA (0.34) | ACHELMNATRPA1PTGS1CACNA1C | |
| SCHEMBL23788293 | 0.84 | ACHE (0.32) | ACHE | |
| SCHEMBL11890580 | 0.82 | CES2 (0.32) | — | |
| SCHEMBL3093413 | 0.82 | MEN1 (0.33) | ACHE | |
| SCHEMBL19682787 | 0.82 | ACHE (0.31) | ACHE | |
| SCHEMBL9945902 | 0.81 | CHRM2 (0.34) | ACHELMNATRPA1PTGS1CACNA1C | |
| SCHEMBL10304822 | 0.81 | ACHE (0.33) | ACHELMNATRPA1PTGS1CACNA1C | |
| SCHEMBL12678215 | 0.79 | ACHE (0.30) | ACHETRPA1 | |
| SCHEMBL23101924 | 0.79 | TSHR (0.31) | — | |
| SCHEMBL24681025 | 0.77 | TRPA1 (0.42) | LMNATRPA1PTGS1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023205475-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS CLOTHO, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-3686197-B1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-06-21 | — | — | EP | disclosed |
| EP-4020081-B1 | COMPOSITION FOR FORMING SILICON-CONTAINING RESIST UNDERLAYER FILM, PATTERNING PROCESS, AND SILICON COMPOUND | SHINETSU CHEMICAL CO (JP) | 2023-05-17 | — | — | EP | disclosed |
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | HIBERCELL, INC. | 2022-12-08 | — | — | US | disclosed |
| WO-2022006039-A1 | COMPOSITIONS AND METHODS FOR MODULATING HAIR GROWTH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2020210828-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | HIBERCELL, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-3686197-A1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2020-07-29 | — | — | EP | disclosed |
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-02 | — | — | US | disclosed |
| WO-2019057112-A1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | 北京赛特明强医药科技有限公司 | 2019-03-28 | — | — | WO | disclosed |
| US-9951071-B2 | Dihydropyridone P1 as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-24 | — | — | US | disclosed |
| EP-2423199-A1 | Substituted imidazoles and their use as pesticides | Pfizer Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| US-20110206607-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | GE HEALTHCARE LIMITED (GB) | 2011-08-25 | — | — | US | disclosed |
| EP-1981853-B1 | SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES | PFIZER LTD (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-7888376-B2 | Cholesteryl ester transfer protein (CETP) inhibitors; atherosclerosis and cardiovascular diseases; N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-4-(trifluoromethyl)thiazol-2-amine; Alzheimer's, atherosclerosis, venous thrombosis, peripheral vascular disease | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| WO-2010142752-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7790770-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | IDH1, IDH2, IDH3A | ACHE 729/4885LMNA 3920/4885TRPA1 4477/4885 |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ACHE 3249/4885LMNA 170/4885TRPA1 3080/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ACHE 3249/4885LMNA 170/4885TRPA1 3080/4885 |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | ACHE 4775/4885LMNA 4561/4885TRPA1 3856/4885 |
| US-20110206607-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | CNR1, CNR2, GPR18 | ACHE 1351/4885LMNA 4441/4885TRPA1 428/4885 |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ACHE 3249/4885LMNA 170/4885TRPA1 3080/4885 |
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | EIF2AK4, GCN1, GNAI2 | ACHE 4622/4885LMNA 3719/4885TRPA1 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.